[
    {
        "drugid": "RxNorm:2591476",
        "drug": {
            "name": "abrocitinib"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and may result in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2106338",
        "drug": {
            "name": "amifampridine"
        },
        "phenotypes": {
            "NAT2": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "NAT2": "Results in higher systemic concentrations and higher adverse reaction risk. Use lowest recommended starting dosage and monitor for adverse reactions. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "NAT2": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2106337",
        "drug": {
            "name": "amifampridine phosphate"
        },
        "phenotypes": {
            "NAT2": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "NAT2": "Results in higher systemic concentrations. Use lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "NAT2": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:725",
        "drug": {
            "name": "amphetamine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:89013",
        "drug": {
            "name": "aripiprazole"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1673265",
        "drug": {
            "name": "aripiprazole lauroxil"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1543543",
        "drug": {
            "name": "belinostat"
        },
        "phenotypes": {
            "UGT1A1": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "UGT1A1": "May result in higher systemic concentrations and higher adverse reaction risk. Reduce starting dose to 750 mg/m2 in poor metabolizers."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "UGT1A1": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2567226",
        "drug": {
            "name": "belzutifan"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer",
            "UGT2B17": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.",
            "UGT2B17": "Might be included in CYP2C19 implication; mind that description might not apply ifone gene is \"Indeterminate\" (generated by script to match CPIC behavior)"
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer",
            "UGT2B17": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2567226",
        "drug": {
            "name": "belzutifan"
        },
        "phenotypes": {
            "CYP2C19": "Indeterminate",
            "UGT2B17": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.",
            "UGT2B17": "Might be included in CYP2C19 implication; mind that description might not apply ifone gene is \"Indeterminate\" (generated by script to match CPIC behavior)"
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Indeterminate",
            "UGT2B17": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2567226",
        "drug": {
            "name": "belzutifan"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer",
            "UGT2B17": "Indeterminate"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and may result in higher adverse reaction risk (anemia, hypoxia). Monitor patients who are poor metabolizers for both genes for adverse reactions.",
            "UGT2B17": "Might be included in CYP2C19 implication; mind that description might not apply ifone gene is \"Indeterminate\" (generated by script to match CPIC behavior)"
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer",
            "UGT2B17": "Indeterminate"
        }
    },
    {
        "drugid": "RxNorm:1658314",
        "drug": {
            "name": "brexpiprazole"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1739745",
        "drug": {
            "name": "brivaracetam"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:1739745",
        "drug": {
            "name": "brivaracetam"
        },
        "phenotypes": {
            "CYP2C19": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Intermediate Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:21241",
        "drug": {
            "name": "clobazam"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:21241",
        "drug": {
            "name": "clobazam"
        },
        "phenotypes": {
            "CYP2C19": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Intermediate Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2626",
        "drug": {
            "name": "clozapine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations. Dosage reductions may be necessary."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1876905",
        "drug": {
            "name": "deutetrabenazine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg)."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:10402",
        "drug": {
            "name": "dronabinol"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.5"
        }
    },
    {
        "drugid": "RxNorm:10402",
        "drug": {
            "name": "dronabinol"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.0"
        }
    },
    {
        "drugid": "RxNorm:10402",
        "drug": {
            "name": "dronabinol"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "1.5"
        }
    },
    {
        "drugid": "RxNorm:10402",
        "drug": {
            "name": "dronabinol"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "1.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "1.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.75"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.5"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.25"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22656.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22655.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.75"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22654.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.5"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.25"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "4.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "2.75"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "3.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "2.5"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "2.25"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "2.0"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "1.5"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "1.75"
        }
    },
    {
        "drugid": "RxNorm:1547220",
        "drug": {
            "name": "eliglustat"
        },
        "phenotypes": {
            "CYP2D6": "Normal Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "1.25"
        }
    },
    {
        "drugid": "RxNorm:2123125",
        "drug": {
            "name": "erdafitinib"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.5"
        }
    },
    {
        "drugid": "RxNorm:2123125",
        "drug": {
            "name": "erdafitinib"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1665509",
        "drug": {
            "name": "flibanserin"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C19": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:328134",
        "drug": {
            "name": "gefitinib"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:73178",
        "drug": {
            "name": "iloperidone"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:51499",
        "drug": {
            "name": "irinotecan"
        },
        "phenotypes": {
            "UGT1A1": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "UGT1A1": "Results in higher systemic active metabolite concentrations and higher adverse reaction risk (severe or life-threatening neutropenia, severe diarrhea). Closely monitor for neutropenia during and after treatment. Consider reducing the starting dosage by at least one level in poor metabolizers and modify the dosage based on individual patient tolerance. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "UGT1A1": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:51499",
        "drug": {
            "name": "irinotecan"
        },
        "phenotypes": {
            "UGT1A1": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "UGT1A1": "Results in higher systemic active metabolite concentrations and higher adverse reaction risk (severe or life-threatening neutropenia, severe diarrhea). Closely monitor for neutropenia during and after treatment. Consider reducing the starting dosage by at least one level in poor metabolizers and modify the dosage based on individual patient tolerance. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "UGT1A1": "Intermediate Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:28863",
        "drug": {
            "name": "lofexidine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "1.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.75"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.5"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.25"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22656.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22655.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.75"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22654.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.5"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.25"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "\u22653.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "4.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "2.75"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "3.0"
        }
    },
    {
        "drugid": "RxNorm:6676",
        "drug": {
            "name": "meclizine"
        },
        "phenotypes": {
            "CYP2D6": "Ultrarapid Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "2.5"
        }
    },
    {
        "drugid": "RxNorm:6915",
        "drug": {
            "name": "metoclopramide"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:30077",
        "drug": {
            "name": "mivacurium"
        },
        "phenotypes": {
            "BCHE": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "BCHE": "Results in higher systemic concentrations and higher adverse reaction risk (prolonged neuromuscular blockade). Avoid use in poor metabolizers."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "BCHE": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:30077",
        "drug": {
            "name": "mivacurium"
        },
        "phenotypes": {
            "BCHE": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "BCHE": "Results in higher systemic concentrations and higher adverse reaction risk (prolonged neuromuscular blockade). Avoid use in poor metabolizers."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "BCHE": "Intermediate Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:274332",
        "drug": {
            "name": "nateglinide"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "Results in higher systemic concentrations and may result in higher adverse reaction risk (hypoglycemia). Dosage reduction is recommended. Increase monitoring frequency for adverse reactions. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.5"
        }
    },
    {
        "drugid": "RxNorm:274332",
        "drug": {
            "name": "nateglinide"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "Results in higher systemic concentrations and may result in higher adverse reaction risk (hypoglycemia). Dosage reduction is recommended. Increase monitoring frequency for adverse reactions. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.0"
        }
    },
    {
        "drugid": "RxNorm:2392230",
        "drug": {
            "name": "oliceridine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk (respiratory depression and sedation). May require less frequent dosing."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:8331",
        "drug": {
            "name": "pimozide"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:2197878",
        "drug": {
            "name": "pitolisant"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations. Use lowest recommended starting dosage. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:8754",
        "drug": {
            "name": "propafenone"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:2360530",
        "drug": {
            "name": "sacituzumab govitecan-hziy"
        },
        "phenotypes": {
            "UGT1A1": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "UGT1A1": "May result in higher systemic concentrations and adverse reaction risk (neutropenia). Monitor for adverse reactions and tolerance to treatment."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "UGT1A1": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2121085",
        "drug": {
            "name": "siponimod"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.5"
        }
    },
    {
        "drugid": "RxNorm:2121085",
        "drug": {
            "name": "siponimod"
        },
        "phenotypes": {
            "CYP2C9": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "0.0"
        }
    },
    {
        "drugid": "RxNorm:2121085",
        "drug": {
            "name": "siponimod"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "1.5"
        }
    },
    {
        "drugid": "RxNorm:2121085",
        "drug": {
            "name": "siponimod"
        },
        "phenotypes": {
            "CYP2C9": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2C9": "Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C9": "1.0"
        }
    },
    {
        "drugid": "RxNorm:10390",
        "drug": {
            "name": "tetrabenazine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:10502",
        "drug": {
            "name": "thioridazine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:1918219",
        "drug": {
            "name": "valbenazine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 1)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section1"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:20352",
        "drug": {
            "name": "carvedilol"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk (dizziness)."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:44281",
        "drug": {
            "name": "cevimeline"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "CYP2D6": "May result in higher adverse reaction risk. Use with caution."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:6038",
        "drug": {
            "name": "isoniazid"
        },
        "phenotypes": {
            "Nonspecific (NAT)": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "Nonspecific (NAT)": "May result in higher systemic concentrations and adverse reaction risk."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "Nonspecific (NAT)": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2600867",
        "drug": {
            "name": "mavacamten"
        },
        "phenotypes": {
            "CYP2C19": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:2600867",
        "drug": {
            "name": "mavacamten"
        },
        "phenotypes": {
            "CYP2C19": "Intermediate Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "CYP2C19": "Results in higher systemic concentrations and may have higher adverse reaction risk (heart failure). Dosage is based on individual response. The dose titration and monitoring schedule accounts for differences due to CYP2C19 genetic variation, so adjustments based on CYP2C19 genotype are not necessary. Refer to FDA labeling for specific dosing recommendations and monitoring."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2C19": "Intermediate Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:662281",
        "drug": {
            "name": "nilotinib"
        },
        "phenotypes": {
            "UGT1A1": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "UGT1A1": "Results in higher adverse reaction risk (hyperbilirubinemia)."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "UGT1A1": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:8076",
        "drug": {
            "name": "perphenazine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    },
    {
        "drugid": "RxNorm:8700",
        "drug": {
            "name": "procainamide"
        },
        "phenotypes": {
            "Nonspecific (NAT)": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "Nonspecific (NAT)": "Alters systemic parent drug and metabolite concentrations. May result in higher adverse reaction risk."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "Nonspecific (NAT)": "Poor Metabolizer"
        }
    },
    {
        "drugid": "RxNorm:119565",
        "drug": {
            "name": "tolterodine"
        },
        "phenotypes": {
            "CYP2D6": "Poor Metabolizer"
        },
        "guideline": {
            "name": "Table of Pharmacogenetic Associations (Section 2)",
            "url": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations#section2"
        },
        "implications": {
            "CYP2D6": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation)."
        },
        "drugrecommendation": "Might be included in implication text (imported from FDA; source only states one text per guideline)",
        "id": 1,
        "version": 1,
        "lookupkey": {
            "CYP2D6": "0.0"
        }
    }
]